ACE2 and infection: The role of ACE2 was definitively confirmed through a genome-wide association study (GWAS) [56], that identified an ACE2 variant (c.357-1203A > G, minor allele frequency 0.2–2%) that reduces by 37% (P = 2.7 × 10 − 8) the expression of the receptor, and therefore reduces by 40% (odds ratio = 0.60, P = 4.5 × 10 − 13) the risk of infection with SARS-CoV-2.